
    
      Study drug: OLP-1002

      Proposed Dose:

        1. 5 microgram twice a week (BIW) for 15 days (Day 1, 4, 8, 11 and 15)

        2. 10 microgram BIW for 15 days (Day 1, 4, 8, 11 and 15)

      Mode of Administration: Subcutaneous injection

      The study will consist of 5 time periods:

        -  Screening period: up to14 days

        -  Washout period: 5 days (± 1 day)

        -  Baseline period: 3 days (± 1 day)

        -  Treatment period: 15 days (± 1 day)

        -  Follow-up period: 30 days from last dose (± 5 days)

      Up to 30 patients will be enrolled in the study and will be randomised in the ratio 1:1:1 to
      the following arms:

        -  Arm A: 10 patients will receive 5 µg BIW OLP-1002

        -  Arm B: 10 patients will receive 10 µg BIW OLP-1002

        -  Arm C: 10 patients will receive Placebo BIW
    
  